DUBLIN, July 9, 2013 /PRNewswire/ --
Research and Markets ( http://www.researchandmarkets.com/research/b9t3dr/top_five_global) has announced the addition of the "Top Five Global Cardiovascular Drug Companies: Performance, Strategies and Competitive Analysis" report to their offering.
The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US $174.8 billion in 2017, growing with a CAGR of 2.9% over the next five years. Top companies are making strategic acquisitions both to expand their global footprints and to take advantage of established business and expertise gained from acquired companies.
The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.
The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:
- Bristol-Myers Squibb
As indicted in the study, the
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved